melem: C(6)N(7)(NH(2))(3); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 73919 |
| CHEBI ID | 38055 |
| SCHEMBL ID | 31245 |
| SCHEMBL ID | 15962521 |
| MeSH ID | M0573339 |
| Synonym |
|---|
| einecs 216-122-4 |
| brn 0027284 |
| 1,3,4,6,7,9,9b-heptaazaphenalene-2,5,8-triamine |
| 2,5,8-triamino-1,3,4,6,7,9,9b-heptaaza-phenalene |
| cyamelurotriamide |
| 1502-47-2 |
| triamino-s-heptazine |
| melem |
| CHEBI:38055 |
| 2,5,8-triamino-tri-s-triazine |
| AKOS000636933 |
| wp6u3u42xl , |
| 4-26-00-04244 (beilstein handbook reference) |
| unii-wp6u3u42xl |
| 1,3,4,6,7,9,9b-heptaazaphenalene, 2,5,8-triamino- |
| SCHEMBL31245 |
| SCHEMBL15962521 |
| DTXSID40164493 |
| 2,4,6,8,10,12,13-heptaazatricyclo[7.3.1.0?,(1)(3)]trideca-1,3,5,7,9,11-hexaene-3,7,11-triamine |
| AS-67257 |
| 1,3,3a1,4,6,7,9-heptaazaphenalene-2,5,8-triamine |
| CS-0110373 |
| Q1919260 |
| D93390 |
| YSWG128 |
| 11-imino-2,4,6,8,10,12,13-heptazatricyclo[7.3.1.05,13]trideca-1(12),2,4,7,9-pentaene-3,7-diamine |
| mfcd00767872 |
| BAA50247 |
| 2,4,6,8,10,12,13-heptaazatricyclo[7.3.1.0?,??]trideca-1,3,5,7,9,11-hexaene-3,7,11-triamine |
| 2,5,8-triamino-1,3,4,6,7,9,9b-heptaazaphenalene |
| delacal 360 |
| delacal 450 |
| Class | Description |
|---|---|
| heptaazaphenalene | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (65.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||